We used data from cohorts of patients with tumors originally classified as HER2- BC by local measurements, enrolled into three large clinical trials performed by the West Germany Study Group (WSG) in early BC: WSG-ADAPT-HR + /HER2- [13], WSG-ADAPT-TN [14], and adjuvant WSG-PlanB [15]. Here, ERBB2 is linked to breast cancer.